Market Overview

Alexion Says Clinical, Statistical Improvement in 2nd Endpoints of Eculizumab Study

Related ALXN
Raptor Announces CEO Succession Plan; Dr. Christopher Starr To Retire As CEO At Year-End 2014, Julie Anne Smith Named President And CEO-Designate
Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers have presented data from a single-arm, open-label, investigator-initiated Phase 2 study of eculizumab (Soliris^®) as an investigational therapy in 14 patients with severe, relapsing neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder. The study met its primary efficacy endpoint with high degrees of clinical and statistical significance. Clinically and statistically significant improvements were also observed in key secondary endpoints. Data were presented today at a Scientific Symposium Oral Session at the American Neurological Association annual meeting in Boston, Mass.^1

Posted-In: News FDA

 

Most Popular

Related Articles (ALXN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free